Laval, Canada

Mohammad Ayub Khan


Average Co-Inventor Count = 3.0

ph-index = 1

Forward Citations = 3(Granted Patents)


Company Filing History:


Years Active: 1999

Loading Chart...
1 patent (USPTO):Explore Patents

Title: **Innovator Spotlight: Mohammad Ayub Khan**

Introduction

Mohammad Ayub Khan, hailing from Chomedey Laval, Canada, is a notable inventor recognized for his contributions to the field of retrovirology. With a focus on innovative solutions for viral particle production, Khan has developed a patent that showcases his expertise and commitment to advancing scientific research.

Latest Patents

Khan holds a significant patent titled "Retroviral vectors pseudotyped with SRV-3 envelope glycoprotein sequences." This invention involves cells that are engineered to produce recombinant retroviral particles. Notably, his patent includes a detailed description of a first vector with a coding region for retroviral long terminal repeats (LTRs) and packaging signals, controlled by an expression control system. By incorporating a tRNA binding site and origins of second strand DNA synthesis, alongside vectors that code for retroviral capsid proteins and envelope glycoproteins, Khan's invention represents a breakthrough in retroviral research.

Career Highlights

Khan is associated with Chiron Corporation, a leading company in the biopharmaceutical sector, where he contributes his expertise in molecular biology and retroviral research. His notable work in developing advanced methods for producing retroviral particles places him at the forefront of his field, enhancing the capabilities of current scientific methods.

Collaborations

Throughout his career, Khan has collaborated with esteemed colleagues, including Robert O. Ralston and John E. Murphy. These partnerships have enabled him to develop innovative solutions and share knowledge within the scientific community, illustrating the importance of teamwork in achieving groundbreaking advancements.

Conclusion

Mohammad Ayub Khan's work exemplifies the spirit of innovation and dedication to scientific excellence. His patent on retroviral vectors highlights his role as a pioneer in the field, potentially paving the way for future research and applications in virology. As he continues his journey at Chiron Corporation, Khan remains a significant figure in the realm of biopharmaceutical innovation.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…